• 16 Aug 2021
• Admin
• News Article

Vtx-801 Receives Us Fda Fast Track Designation For The Treatment Of Wilson Disease

Vivet Therapeutics ("Vivet"), A Clinical-Stage Biotechnology Company, And Pfizer Inc. (Nyse: Pfe) Announced The U.S. Food And Drug Administration (Fda) Has Granted Fast Track Designation To Vtx-801, Vivet'S Clinical-Stage Gene Therapy For The Treatment Of Wilson Disease - A Rare, Genetic Disorder That Reduces The Ability Of The Liver And Other Tissues To Regulate Copper Levels, Causing Severe Hepatic Damage, Neurological Symptoms, And Potentially Death. The Fda&Rsquo;S Fast Track Program Is Designed To Facilitate The Development, And Expedite The Review Of, Novel Potential Therapies That Are Designed To Treat Serious Conditions And Fill Unmet Medical Need. Vtx-801 Is A Novel Investigational Gene Therapy To Be Evaluated In A Phase 1/2 Clinical TrialTo Determine The Safety, Tolerability, And Pharmacological Activity Of A Single Intravenous Infusion In Adult Patients With Wilson Disease. Pfizer Is Collaborating With Vivet On The Clinical Supply Of Vtx-801 For The Phase 1/2 Clinical Trial."The Fda'S Decision To Grant Vtx-801 Fast Track Designation Underscores The Urgent Need For New Therapeutic Options To Address This Devastating Disease, Which, If Left Untreated, Can Be Fatal," Said Seng Cheng, Senior Vice President And Chief Scientific Officer Of Pfizer'S Rare Disease Research Unit. "We Are Pleased To Collaborate With Vivet On This Important Development Program, Which We Believe, If Successful, Could Make A Meaningful Difference In The Lives Of Patients Living With Wilson Disease."Dr. Michael Schilsky, Principal Investigator At Yale University School Of Medicine (Connecticut, United States), Said, "We Are Proud To Participate In This Important Clinical Trial. If Vtx-801 Is Successfully Developed, It Has The Potential To Be A Truly Innovative Medicine With The Ability To Restore Copper Metabolism After A Single Injection, Addressing Significant Unmet Medical Needs For Patients With Wilson Disease.""With The Fda'S Authorization Of The Ind Application For Vtx-801 - Combined With Pfizer&Rsquo;S State-Of-The-Art Gene Therapy Manufacturing Capabilities - We Are Well-Positioned To Rapidly Advance Development Of This Potential Therapy," Concluded Jean-Philippe Combal, Ceo And Co-Founder Of Vivet. About Fast Track DesignationFast Track Is A Process Designed To Facilitate The Development, And Expedite The Review Of, Drugs To Treat Serious Conditions That Address An Unmet Medical Need, By Providing A Therapy Where None Exists Or Providing A Therapy Which May Be Potentially Better And Shows Some Advantage Over Available Therapy. Fast Track Designation Includes Opportunities For More Frequent Meetings With The Fda To Discuss Trial Design, Development Plans, Data Needed To Support Drug Approval, Submission Of A New Drug Application (Nda) On A Rolling Basis, And Eligibility For Accelerated Approval And Priority Review, If Relevant Criteria Are Met.